Phenomic’s mission is to raise the survival curve for the hardest to treat solid tumors (e.g., colorectal, pancreatic, breast cancers). We believe the reason why drugs for these cancers have not translated well in the clinic historically is that they were largely discovered and studied in models that do not account for the diversity of cell types present in human tumors. To address this challenge, we have built an ML-powered transcriptomics platform that allows us to understand the interactions of all the cell types in these tumors to identify compelling targets and a system to test our drugs in human tumor explants thus delivering translational insights during our discovery process.
Our lead program is a CD3 engager that uses a novel targeting approach identified by our platform that should be able to overcome limitations of traditional tumor-associated antigens. This program is generating compelling results in challenging cancers and is now at a development candidate stage demonstrating Phenomic’s ability to identify novel high-impact, druggable targets.
Company Details
- Employees
- 22
- Founded
- -
- Address
- 180 John Street, Toronto,ontario M5t 1x5,canada
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://phenomic.ai
- Keywords
- Representative jobs.
- HQ
- Toronto, Ontario
Phenomic Questions
Phenomic's website is https://phenomic.ai
Phenomic's LinkedIn profile is https://www.linkedin.com/company/phenomic
Phenomic has
22 employees.
View email and phone details for 22
employees at Phenomic.
Phenomic's industry is
Biotechnology Research
Phenomic's top competitors are
Ccrm,
Valence Labs,
Bluerock Therapeutics,
Proteinqure,
Nomic Bio,
Shyftbase,
Recursion,
Cyclica (Acquired By Recursion, Nasdaq: Rxrx),
Nura Bio,
Deep Genomics.
Phenomic's categories are Biotechnology Research
Phenomic's founding year is 2017
